

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **February 26, 2005**

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number **1-11479**

AngioDynamics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

11-3146460

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

603 Queensbury Avenue, Queensbury, New York

12804

(Address of principal executive offices)

(Zip Code)

(518) 798-1215

Registrant's telephone number, including area code

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of January 7, 2005, there were 10,772,286 shares of the issuer's common stock outstanding.

Explanation

AngioDynamics, Inc. (the "Company") is filing this amendment solely for the purpose of amending Item 5. "Other Information", and Item 6. "Exhibits", to add the exhibits to be filed herewith.

Item 5. Other Information

On January 15, 2005, the Board of Directors of the Company, acting on the recommendation of the Governance and Nominating Committee of the Board, approved the following schedule of fees for the directors of the Company who are not otherwise officers or employees of the Company or any of its subsidiaries or affiliates (the "Non-Employee Directors"), to be effective retroactive for meetings held on or after January 1, 2005:

Annual Cash Retainer (payable in quarterly installments):	
All Board Members	\$24,000
Additional Cash Retainer (payable in quarterly installments):	
Audit Committee Chair	\$12,000
Chairman of the Board	\$24,000
Board and Committee Meeting Fees:	
Board	\$1,500/meeting
Committees	
Chairman	\$1,500/meeting
Members	\$750/meeting

Equity Grants:

Initial grant to new directors:

Option for 25,000 shares (48-month vesting period) under the Company's 2004 Stock and Incentive Award Plan (the "2004 Plan")

Annual grant to each director:

Option for 6,000 shares (36-month vesting period) under the 2004 Plan

The Board also determined that each director is required to purchase or own at least 1,000 shares of the Company's stock per year for the first three years of Board membership until the director owns 3,000 shares, and, thereafter, the director must maintain ownership of a minimum of 3,000 shares.

In addition, on January 15, 2005, the Compensation Committee of the Board of Directors approved the individual annual performance objectives, or MBO's, under the Company's Management Profitability Bonus Program (the "Program") for fiscal 2005 for Eammon P. Hobbs, the Company's President and Chief Executive Officer. Mr. Hobbs' fiscal 2005 MBO's generally consist of a combination of one or more Company financial benchmarks, including objectives relating to revenues, gross margins, EBIT, expense limitations and similar goals, and specific personal performance objectives set by the Compensation Committee. These objectives generally relate to matters within Mr. Hobbs'

areas of responsibility. The various MBO's were assigned percentage values in accordance with their importance to the Company's achievement of its overall objectives.

Item 6. **Exhibits**

<u>No.</u>	<u>Description</u>
10.1	Summary of the Compensation of Directors of AngioDynamics, Inc.
31.1	Certification pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification pursuant to Title 18, United States Code, Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
32.2	Certification pursuant to Title 18, United States Code, Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

*Previously filed as an exhibit to the Form 10-Q as originally filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AngioDynamics, Inc.

(Registrant)

Date: August 25, 2005

/s/ Eamonn P. Hobbs

Eamonn P. Hobbs,
President, Chief Executive Officer

Date: August 25, 2005

/s/ Joseph G. Gerardi

Joseph G. Gerardi,
Vice President - Chief Financial
Officer (Principal Financial and Chief
Accounting Officer)

<u>No.</u>	<u>Description</u>	
10.1	Summary of the Compensation of the Directors of AngioDynamics, Inc.	
	Annual Cash Retainer (payable in quarterly installments):	
	All Board Members	\$24,000
	Additional Cash Retainer (payable in quarterly installments):	
	Audit Committee Chair	\$12,000
	Chairman of the Board	\$24,000
	Board and Committee Meeting Fees:	
	Board	\$1,500/meeting
	Committees	
	Chairman	\$1,500/meeting
	Members	\$750/meeting
	Equity Grants:	
	Initial grant to new directors:	
	Option for 25,000 shares (48-month vesting period) under the Company's 2004 Stock and Incentive Award Plan (the "2004 Plan")	
	Annual grant to each director:	
	Option for 6,000 shares (36-month vesting period) under the 2004 Plan	

Certification Pursuant to Rule 13a-14(a) or 15d-14
Under the Securities Exchange Act of 1934

I, Eamonn P. Hobbs, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of AngioDynamics, Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: August 25, 2005

/s/ Eamonn P. Hobbs

Eamonn P. Hobbs,
President, Chief Executive Officer

Certification Pursuant to Rule 13a-14(a) or 15d-14
Under the Securities Exchange Act of 1934

I, Joseph G. Gerardi, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of AngioDynamics, Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: August 25, 2005

/s/ Joseph G. Gerardi

Joseph G. Gerardi,
Vice President - Chief Financial
Officer (Principal Financial and
Chief Accounting Officer)
